[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nebraska Methodist Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100609924","phase-3-levetiracetam-compared-to-magnesium-sulfate-for-prevention-of-eclamptic-seizure-100609924",false,"NCT07220902","Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure","Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure: A Randomized Controlled Trial \"LEVMag Trial\"","LEVMag","Inclusion Criteria:\n\n* Pregnant or postpartum women aged 19 years or older\n* Diagnosed with preeclampsia with severe features, superimposed preeclampsia or HELLP syndrome\n* At risk for eclampsia and eligible for seizure prophylaxis\n* Less than 2 hours exposure to magnesium sulfate or greater than 48 hours since last dose.\n* Admitted or plan to proceed with delivery\n\nExclusion Criteria:\n\n* \\\u003C32 weeks estimated gestational age\n* History of epilepsy or seizure disorders unrelated to pregnancy\n* Allergy or contraindication to Levetiracetam or Magnesium Sulfate\n* Severe renal impairment (Oliguria \\\u003C120ml in 4 hours)\n* Plan for neonatal comfort care","FEMALE","19 Years",{"count":20,"type":21},1240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in the two groups. Since side effects can be a significant problem with magnesium sulfate and these patients are at significant risk of life threatening complications, we also plan to evaluate several secondary outcomes in the mothers and the babies, including:\n\nsevere allergic reaction, magnesium toxicity, ICU admission, hospital readmission, transfusion for any reason, pulmonary edema, cardiomyopathy, Posterior Reversible Encephalopathy Syndrome, eclamptic seizure, loss of vision, stroke, renal injury requiring dialysis, cardiac arrest, maternal death, unexpected stillbirth or neonatal death, NICU admission, Apgars and length of neonatal respiratory support.",[27,28],"Severe Preeclampsia","Eclampsia Preeclampsia",[30,31,32,33,34,35,36,15,37],"Seizure","Prophylaxis","Preeclampsia","Eclampsia","Keppra","Levetiracetam","Magnesium","Equivalence","NOT_YET_RECRUITING","2025-10-22",{"date":41,"type":42},"2025-10-24","ACTUAL",{"date":44,"type":21},"2026-01-01",{"date":46,"type":21},"2034-07",{"name":48,"class":49},"Nebraska Methodist Health System","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100594711","phase-4-postpartum-evaluation-of-nifedipine-and-enalapril-for-hypertension-100594711","NCT07023003","Postpartum Evaluation of Nifedipine and Enalapril for Hypertension","Postpartum Evaluation of Antihypertensives for Control of Hypertension: A Randomized Controlled Equivalence Study","PEACE","Inclusion Criteria:\n\n1. admitted for delivery by cesarean or vaginal delivery\n2. 24 weeks gestation or greater\n3. Pregnancy related hypertension(HTN) or chronic hypertension. Pregnancy related hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN in patients without CHTN.\n\nExclusion Criteria:\n\n1. Absolute contraindication to either nifedipine or enalapril Relative contraindications will be reviewed with PI.\n2. Persistent HR \\\u003C60 or \\>110\n3. Native language other than English",{"count":60,"type":21},850,[62],"PHASE4","This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine.\n\nInvestigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study.\n\nThe only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.",[65],"Hypertension in Pregnancy",[67,68,69,70,71],"Hypertension","Postpartum","Enalapril","Nifedipine","Readmission","RECRUITING","2025-10-20",{"date":39,"type":42},{"date":76,"type":42},"2025-07-11",{"date":78,"type":21},"2028-12",{"name":48,"class":49},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":50},"100463036","phase-4-labetalol-or-nifedipine-for-control-of-postpartum-hypertension-a-randomized-controlled-trial-100463036","NCT05309460","Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial","Inclusion Criteria:\n\nAny patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension.\n\nExclusion Criteria:\n\nHistory of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema\n\n* Contraindication to either Nifedipine or Labetalol\n* HR \\\u003C60 or \\>110\n* Native language other than English or Spanish",{"count":87,"type":21},600,[62],"Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.",[91,65],"Postpartum Preeclampsia",[70,93,68,67,32,94],"Labetalol","Pregnancy","2024-04-10",{"date":97,"type":42},"2024-04-12",{"date":99,"type":42},"2022-06-20",{"date":101,"type":21},"2024-12-01",{"name":48,"class":49},""]